Sage Therapeutics Inc [NASDAQ: SAGE] plunged by -$0.22 during the normal trading session on Tuesday and reaching a high of $8.855 during the day while it closed the day at $8.75.
Sage Therapeutics Inc stock has also loss -4.58% of its value over the past 7 days. However, SAGE stock has inclined by 17.61% in the 3 months of the year. Over the past six months meanwhile, it has gained 23.59% and lost -28.10% year-on date.
The market cap for SAGE stock reached $548.00 million, with 62.54 million shares outstanding and 55.09 million shares in the current float. Compared to the average trading volume of 1.70M shares, SAGE reached a trading volume of 10956223 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Sage Therapeutics Inc [SAGE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SAGE shares is $8.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SAGE stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Sage Therapeutics Inc shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on March 11, 2025. The new note on the price target was released on November 21, 2024, representing the official price target for Sage Therapeutics Inc stock. On October 04, 2024, analysts decreased their price target for SAGE shares from 10 to 4.
The Price to Book ratio for the last quarter was 1.34, with the Price to Cash per share for the same quarter was set at 6.77.
SAGE stock trade performance evaluation
Sage Therapeutics Inc [SAGE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.58. With this latest performance, SAGE shares dropped by -5.91% in over the last four-week period, additionally plugging by 23.59% over the last 6 months – not to mention a rise of 61.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SAGE stock in for the last two-week period is set at 49.87, with the RSI for the last a single of trading hit 0.15, and the three-weeks RSI is set at 0.20 for Sage Therapeutics Inc [SAGE]. The present Moving Average for the last 50 days of trading for this stock 7.92, while it was recorded at 9.02 for the last single week of trading, and 7.08 for the last 200 days.
Sage Therapeutics Inc [SAGE]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Sage Therapeutics Inc [SAGE] shares currently have an operating margin of -758.97% and a Gross Margin at 81.37%. Sage Therapeutics Inc’s Net Margin is presently recorded at -747.61%.
Sage Therapeutics Inc (SAGE) Capital Structure & Debt Analysis
According to recent financial data for Sage Therapeutics Inc. ( SAGE), the Return on Equity (ROE) stands at -63.53%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -57.29%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Sage Therapeutics Inc’s Return on Invested Capital (ROIC) is -84.40%, showcasing its effectiveness in deploying capital for earnings.
Sage Therapeutics Inc (SAGE) Efficiency & Liquidity Metrics
Based on Sage Therapeutics Inc’s (SAGE) latest financial statements, the Debt-to-Equity Ratio is 0.03%, indicating its reliance on debt financing relative to shareholder equity.
Sage Therapeutics Inc (SAGE) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Sage Therapeutics Inc. (SAGE) effectively leverages its workforce, generating an average of -$1003966.01 per employee. The company’s liquidity position is robust, with a Current Ratio of 9.13% and a Quick Ratio of 9.13%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Sage Therapeutics Inc [SAGE] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SAGE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Sage Therapeutics Inc go to 34.64%.
Sage Therapeutics Inc [SAGE]: Institutional Ownership
There are presently around $83.81%, or 93.54% of SAGE stock, in the hands of institutional investors. The top three institutional holders of SAGE stocks are: VANGUARD GROUP INC with ownership of 6.42 million shares, which is approximately 10.5988%. FMR LLC, holding 5.82 million shares of the stock with an approximate value of $$63.24 million in SAGE stocks shares; and FMR LLC, currently with $$59.52 million in SAGE stock with ownership which is approximately 9.0531%.
